US20020156434A1
(en)
*
|
1998-03-13 |
2002-10-24 |
Minimed Inc. |
Stabilizing catheter for protein drug delivery
|
US6703381B1
(en)
*
|
1998-08-14 |
2004-03-09 |
Nobex Corporation |
Methods for delivery therapeutic compounds across the blood-brain barrier
|
US7375096B1
(en)
*
|
1998-12-04 |
2008-05-20 |
California Institute Of Technology |
Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network
|
US6716452B1
(en)
*
|
2000-08-22 |
2004-04-06 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
US7060708B2
(en)
*
|
1999-03-10 |
2006-06-13 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
US6713454B1
(en)
*
|
1999-09-13 |
2004-03-30 |
Nobex Corporation |
Prodrugs of etoposide and etoposide analogs
|
JP4027663B2
(en)
*
|
1999-10-04 |
2007-12-26 |
ネクター セラピューティックス エイエル,コーポレイション |
Polymer stabilized neuropeptide
|
US6638906B1
(en)
|
1999-12-13 |
2003-10-28 |
Nobex Corporation |
Amphiphilic polymers and polypeptide conjugates comprising same
|
US6596306B1
(en)
*
|
2000-07-07 |
2003-07-22 |
David Ho Sue San Ho |
Drug delivery system:formulation for fat-soluble drugs
|
US20020099013A1
(en)
*
|
2000-11-14 |
2002-07-25 |
Thomas Piccariello |
Active agent delivery systems and methods for protecting and administering active agents
|
US7163918B2
(en)
|
2000-08-22 |
2007-01-16 |
New River Pharmaceuticals Inc. |
Iodothyronine compositions
|
WO2003079972A2
(en)
*
|
2002-02-22 |
2003-10-02 |
New River Parmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
WO2002024116A1
(en)
*
|
2000-09-20 |
2002-03-28 |
Shahinian, Lee, Jr. |
Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications
|
FR2814951B1
(en)
*
|
2000-10-06 |
2003-01-17 |
Flamel Tech Sa |
COLLOIDAL SUSPENSION OF SUBMICRONIC PARTICLES FOR VECTORIZATION OF ACTIVE HYDROPHILIC PRINCIPLES (INSULIN) AND THEIR METHOD OF PREPARATION
|
US8394813B2
(en)
|
2000-11-14 |
2013-03-12 |
Shire Llc |
Active agent delivery systems and methods for protecting and administering active agents
|
TWI321054B
(en)
*
|
2000-12-19 |
2010-03-01 |
California Inst Of Techn |
Compositions containing inclusion complexes
|
US7060675B2
(en)
*
|
2001-02-15 |
2006-06-13 |
Nobex Corporation |
Methods of treating diabetes mellitus
|
DE60228941D1
(en)
|
2001-03-08 |
2008-10-30 |
Univ Pennsylvania |
Faciale amphiphile polymere als antiinfektiöse mittel
|
FR2822834B1
(en)
*
|
2001-04-02 |
2005-02-25 |
Flamel Tech Sa |
COLLOIDAL SUSPENSION OF NANOPARTICLES BASED ON AMPHIPHILIC COPOLYMERS FOR VECTORIZATION OF ACTIVE INGREDIENTS AND THEIR METHOD OF PREPARATION
|
TR200400295T2
(en)
*
|
2001-05-21 |
2005-04-21 |
Nektar Therapeutics |
Lung delivery of chemically modified insulin
|
US7713932B2
(en)
|
2001-06-04 |
2010-05-11 |
Biocon Limited |
Calcitonin drug-oligomer conjugates, and uses thereof
|
US6835802B2
(en)
|
2001-06-04 |
2004-12-28 |
Nobex Corporation |
Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
|
US6828297B2
(en)
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6713452B2
(en)
|
2001-06-04 |
2004-03-30 |
Nobex Corporation |
Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US6828305B2
(en)
|
2001-06-04 |
2004-12-07 |
Nobex Corporation |
Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
|
US7198945B2
(en)
*
|
2001-08-09 |
2007-04-03 |
Teruyuki Nagamune |
Cell having modified cell membrane
|
US20070066537A1
(en)
*
|
2002-02-22 |
2007-03-22 |
New River Pharmaceuticals Inc. |
Compounds and compositions for prevention of overdose of oxycodone
|
US20060014697A1
(en)
|
2001-08-22 |
2006-01-19 |
Travis Mickle |
Pharmaceutical compositions for prevention of overdose or abuse
|
US7338939B2
(en)
*
|
2003-09-30 |
2008-03-04 |
New River Pharmaceuticals Inc. |
Abuse-resistant hydrocodone compounds
|
US7375082B2
(en)
*
|
2002-02-22 |
2008-05-20 |
Shire Llc |
Abuse-resistant hydrocodone compounds
|
US7169752B2
(en)
|
2003-09-30 |
2007-01-30 |
New River Pharmaceuticals Inc. |
Compounds and compositions for prevention of overdose of oxycodone
|
US6770625B2
(en)
*
|
2001-09-07 |
2004-08-03 |
Nobex Corporation |
Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
|
EP1430082B1
(en)
*
|
2001-09-07 |
2009-10-28 |
Biocon Limited |
Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
US6913903B2
(en)
*
|
2001-09-07 |
2005-07-05 |
Nobex Corporation |
Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
|
US7030082B2
(en)
|
2001-09-07 |
2006-04-18 |
Nobex Corporation |
Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
|
UA78726C2
(en)
*
|
2001-11-01 |
2007-04-25 |
Sciclone Pharmaceuticals Inc |
Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
|
US20030114460A1
(en)
*
|
2001-12-14 |
2003-06-19 |
Allergan Sales, Inc. |
Pharmaceutical conjugates with enhanced pharmacokinetic characteristics
|
CA2477004C
(en)
*
|
2002-02-22 |
2011-05-10 |
Thomas Piccariello |
Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
|
US7700561B2
(en)
*
|
2002-02-22 |
2010-04-20 |
Shire Llc |
Abuse-resistant amphetamine prodrugs
|
US7659253B2
(en)
|
2002-02-22 |
2010-02-09 |
Shire Llc |
Abuse-resistant amphetamine prodrugs
|
US7105486B2
(en)
*
|
2002-02-22 |
2006-09-12 |
New River Pharmaceuticals Inc. |
Abuse-resistant amphetamine compounds
|
FR2840614B1
(en)
|
2002-06-07 |
2004-08-27 |
Flamel Tech Sa |
POLYAMINOACIDS FUNCTIONALIZED BY ALPHA-TOCOPHEROL AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS
|
AU2003236521A1
(en)
*
|
2002-06-13 |
2003-12-31 |
Nobex Corporation |
Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
|
FR2843117B1
(en)
*
|
2002-07-30 |
2004-10-15 |
Flamel Tech Sa |
POLYAMINOACIDS FUNCTIONALIZED BY AT LEAST ONE HYDROPHOBIC GROUP AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS
|
PT1534340E
(en)
|
2002-09-06 |
2012-03-13 |
Cerulean Pharma Inc |
Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
|
US20040152769A1
(en)
*
|
2002-11-09 |
2004-08-05 |
Ekwuribe Nnochiri Nkem |
Modified carbamate-containing prodrugs and methods of synthesizing same
|
US7897567B2
(en)
*
|
2002-11-25 |
2011-03-01 |
Sciclone Pharmaceuticals, Inc. |
Methods of protecting against radiation damage using alpha thymosin
|
BR0316560A
(en)
*
|
2002-11-26 |
2005-10-04 |
Nobex Corp |
Natriuretic Compound Conjugate, Pharmaceutical Formulation, Method of Treating a Condition, Method of Preparing the Natriuretic Compound Conjugate, Modified Pro-Polynatriuretic Peptide Conjugate, Natriuretic Peptide Analog, hbnp Analogue, Compound, and Method of Preparing a Compound
|
US7648962B2
(en)
|
2002-11-26 |
2010-01-19 |
Biocon Limited |
Natriuretic compounds, conjugates, and uses thereof
|
US8133881B2
(en)
|
2003-01-13 |
2012-03-13 |
Shire Llc |
Carbohydrate conjugates to prevent abuse of controlled substances
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
EP1596887B1
(en)
|
2003-02-26 |
2022-03-23 |
Nektar Therapeutics |
Polymer-factor viii moiety conjugates
|
EP1610805A2
(en)
*
|
2003-03-10 |
2006-01-04 |
Biogen Idec Inc. |
Thiol-mediated drug attachment to targeting peptides
|
AU2004222272B2
(en)
*
|
2003-03-17 |
2010-12-23 |
The Trustees Of The University Of Pennsylvania |
Facially amphiphilic polymers and oligomers and uses thereof
|
US20100311656A1
(en)
*
|
2003-04-23 |
2010-12-09 |
Sciclone Pharmaceuticals, Inc. |
Treatment or prevention of respiratory viral infections with alpha thymosin peptides
|
EP1626748B1
(en)
|
2003-05-13 |
2012-07-11 |
Medtronic, Inc. |
Moisture curable materials for delivery of agents, methods, and medical devices
|
SI1644019T2
(en)
|
2003-05-29 |
2018-04-30 |
Shire Llc |
Abuse resistant amphetamine compounds
|
BRPI0412265A
(en)
|
2003-07-23 |
2006-09-05 |
Novartis Ag |
use of calcitonin in osteoarthritis
|
EP2085406A1
(en)
*
|
2003-07-25 |
2009-08-05 |
ConjuChem Biotechnologies Inc. |
Long lasting insulin derivatives and methods thereof
|
MXPA06003619A
(en)
*
|
2003-09-30 |
2008-01-14 |
New River Pharmaceuticals Inc |
Pharmaceutical compositions for prevention of overdose or abuse.
|
EP1525890A1
(en)
|
2003-10-02 |
2005-04-27 |
Complex Biosystems GmbH |
Protein-Proteophore complexes
|
FR2860516B1
(en)
*
|
2003-10-03 |
2006-01-13 |
Flamel Tech Sa |
TELECHELIC HOMOPOLYAMINOACIDES FUNCTIONALIZED BY HYDROPHOBIC GROUPS AND THEIR PARTICULARLY THERAPEUTIC APPLICATIONS
|
US8222456B2
(en)
*
|
2004-01-23 |
2012-07-17 |
The Trustees Of The University Of Pennsylvania |
Facially amphiphilic polyaryl and polyarylalkynyl polymers and oligomers and uses thereof
|
DE102004009287A1
(en)
*
|
2004-02-26 |
2005-09-15 |
Institut Für Neue Materialien Gem. Gmbh |
Amphiphilic nanoparticles
|
US8329958B2
(en)
|
2004-07-02 |
2012-12-11 |
Biocon Limited |
Combinatorial synthesis of PEG oligomer libraries
|
EP2626368B1
(en)
|
2004-07-19 |
2016-12-21 |
Biocon Limited |
Insulin-oligomer conjugates, formulations and uses thereof
|
WO2006017541A2
(en)
*
|
2004-08-03 |
2006-02-16 |
Emisphere Technologies, Inc. |
Antidiabetic oral insulin-biguanide combination
|
US9028852B2
(en)
*
|
2004-09-07 |
2015-05-12 |
3M Innovative Properties Company |
Cationic antiseptic compositions and methods of use
|
US20060063834A1
(en)
*
|
2004-09-09 |
2006-03-23 |
Frangioni John V |
Substituted adamantanes, and methods of making the same
|
US7402652B2
(en)
*
|
2004-09-14 |
2008-07-22 |
Miller Landon C G |
Baclofen conjugate and a pharmaceutical composition for treatment of neuronal disorders
|
WO2006076471A2
(en)
*
|
2005-01-12 |
2006-07-20 |
Nobex Corporation |
Bnp conjugates and methods of use
|
EP1843790A2
(en)
*
|
2005-01-27 |
2007-10-17 |
Novo Nordisk A/S |
Insulin derivatives conjugated with structurally well defined branched polymers
|
US7741431B2
(en)
*
|
2005-02-01 |
2010-06-22 |
The United States Of America As Represented By The Secretary Of The Army |
Liposomes containing novel targeting and/or fusogenic peptides, preparations containing them and therapeutic use thereof
|
US20090220587A1
(en)
*
|
2005-02-01 |
2009-09-03 |
United State Army |
Liposomal drug delivery constructs targeted by lipid-conjugated peptide ligands
|
US20080171695A1
(en)
*
|
2005-02-02 |
2008-07-17 |
Novo Nordisk A/S |
Insulin Derivatives
|
JP2008531585A
(en)
*
|
2005-02-25 |
2008-08-14 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Surface amphiphilic polymers and oligomers, their compositions and their use in cancer treatment methods
|
BRPI0520362B1
(en)
*
|
2005-07-08 |
2017-10-17 |
Biocon Limited |
PREPARATION OF INSULIN CONJUGATES
|
DK1934252T3
(en)
*
|
2005-10-13 |
2015-08-31 |
Biocon Ltd |
METHOD FOR PRODUCING insulin conjugates
|
JP2009515993A
(en)
|
2005-11-17 |
2009-04-16 |
ノバルティス アクチエンゲゼルシャフト |
Pharmaceutical composition
|
US20070142287A1
(en)
*
|
2005-12-20 |
2007-06-21 |
Biomed Solutions, Llc |
Compositions And Methods For Treatment Of Cancer
|
CA2634034A1
(en)
|
2005-12-20 |
2007-06-28 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
ES2712942T3
(en)
|
2006-03-10 |
2019-05-16 |
Wyeth Llc |
Anti-5T4 antibodies and uses thereof
|
CA2647143A1
(en)
|
2006-03-30 |
2007-10-11 |
Palatin Technologies, Inc. |
Cyclic natriuretic peptide constructs
|
AU2007233123A1
(en)
*
|
2006-03-30 |
2007-10-11 |
Palatin Technologies, Inc. |
Linear natriuretic peptide constructs
|
US8580746B2
(en)
*
|
2006-03-30 |
2013-11-12 |
Palatin Technologies, Inc. |
Amide linkage cyclic natriuretic peptide constructs
|
CN101573133B
(en)
|
2006-07-31 |
2014-08-27 |
诺沃-诺迪斯克有限公司 |
PEGylated, extended insulins
|
EP2404934A1
(en)
|
2006-09-22 |
2012-01-11 |
Novo Nordisk A/S |
Protease resistant insulin analogues
|
WO2008049711A1
(en)
|
2006-10-27 |
2008-05-02 |
Novo Nordisk A/S |
Peptide extended insulins
|
JP2010516625A
(en)
|
2007-01-24 |
2010-05-20 |
インサート セラピューティクス, インコーポレイテッド |
Polymer-drug conjugates with tether groups for controlled drug delivery
|
WO2008132224A2
(en)
|
2007-04-30 |
2008-11-06 |
Novo Nordisk A/S |
Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
EP2170930B3
(en)
|
2007-06-04 |
2013-10-02 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
CN101790379A
(en)
*
|
2007-06-27 |
2010-07-28 |
萨摩斯药品有限责任公司 |
Multi-day delivery of biologically active substances
|
US7776827B2
(en)
*
|
2007-07-27 |
2010-08-17 |
Immuneregen Biosciences, Inc. |
Method of using substance P analogs for treatment amelioration of myelodysplastic syndrome
|
RU2453332C2
(en)
|
2007-10-16 |
2012-06-20 |
Байокон Лимитид |
Solid pharmaceutical composition (versions) and method for controlling glucose concentration therewith, method for preparing solid pharmaceutical compositions (versions), tablet (versions) and method for making amorphous particles
|
WO2009112583A2
(en)
|
2008-03-14 |
2009-09-17 |
Novo Nordisk A/S |
Protease-stabilized insulin analogues
|
AU2009226910B2
(en)
|
2008-03-18 |
2014-02-06 |
Novo Nordisk A/S |
Protease stabilized, acylated insulin analogues
|
US20090271021A1
(en)
*
|
2008-04-28 |
2009-10-29 |
Popp Shane M |
Execution system for the monitoring and execution of insulin manufacture
|
JP2011522828A
(en)
|
2008-06-04 |
2011-08-04 |
シナジー ファーマシューティカルズ インコーポレイテッド |
Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer, and other disorders
|
AU2009270833B2
(en)
|
2008-07-16 |
2015-02-19 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
US20100330033A1
(en)
*
|
2009-04-16 |
2010-12-30 |
Nian Wu |
Protein-carrier conjugates
|
WO2011003633A1
(en)
|
2009-07-06 |
2011-01-13 |
Alize Pharma Ii |
Pegylated l-asparaginase
|
AU2010323117B2
(en)
|
2009-11-25 |
2015-09-03 |
Capsugel Belgium Nv |
Mucosal delivery compositions comprising a peptide complexed with a crown comppound and/or a counter ion
|
EP2550362B1
(en)
|
2010-03-25 |
2017-01-04 |
Oregon Health&Science University |
Cmv glycoproteins and recombinant vectors
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
US20120202890A1
(en)
*
|
2011-02-08 |
2012-08-09 |
Nian Wu |
Polymer-carbohydrate-lipid conjugates
|
WO2012158962A2
(en)
*
|
2011-05-18 |
2012-11-22 |
Eumederis Pharmaceuticals, Inc. |
Improved peptide pharmaceuticals
|
CN111701028A
(en)
|
2011-05-18 |
2020-09-25 |
梅德瑞斯糖尿病有限责任公司 |
Improved peptide medicine for insulin resistance
|
PT2691530T
(en)
|
2011-06-10 |
2018-05-10 |
Univ Oregon Health & Science |
Cmv glycoproteins and recombinant vectors
|
US8883177B2
(en)
|
2011-06-28 |
2014-11-11 |
Nian Wu |
Pharmaceutical compositions for parenteral administration
|
KR20230156804A
(en)
|
2011-06-28 |
2023-11-14 |
이노비오 파마수티컬즈, 인크. |
A miniminally invasive dermal electroporation device
|
US20130189754A1
(en)
|
2011-09-12 |
2013-07-25 |
International Aids Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
|
US9402894B2
(en)
|
2011-10-27 |
2016-08-02 |
International Aids Vaccine Initiative |
Viral particles derived from an enveloped virus
|
CA3111357A1
(en)
|
2011-12-23 |
2013-06-27 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
AU2013247047A1
(en)
|
2012-04-11 |
2014-10-23 |
Novo Nordisk A/S |
Insulin formulations
|
ES2631608T3
(en)
|
2012-06-27 |
2017-09-01 |
International Aids Vaccine Initiative |
Env-glycoprotein variant of HIV-1
|
WO2014055493A1
(en)
|
2012-10-02 |
2014-04-10 |
Cerulean Pharma Inc. |
Methods and systems for polymer precipitation and generation of particles
|
EP3434696A1
(en)
*
|
2012-11-20 |
2019-01-30 |
Mederis Diabetes, LLC |
Improved peptide pharmaceuticals for insulin resistance
|
DK3444281T3
(en)
|
2012-11-20 |
2022-02-07 |
Eumederis Pharmaceuticals Inc |
IMPROVED PEPTID MEDICINES
|
US9707276B2
(en)
|
2012-12-03 |
2017-07-18 |
Merck Sharp & Dohme Corp. |
O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues
|
EP2958577A2
(en)
|
2013-02-25 |
2015-12-30 |
Synergy Pharmaceuticals Inc. |
Guanylate cyclase receptor agonists for use in colonic cleansing
|
WO2014151206A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
CA2905435A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
EP3004138B1
(en)
|
2013-06-05 |
2024-03-13 |
Bausch Health Ireland Limited |
Ultra-pure agonists of guanylate cyclase c, method of making and using same
|
AU2014305843B2
(en)
|
2013-08-09 |
2019-08-29 |
Ardelyx, Inc. |
Compounds and methods for inhibiting phosphate transport
|
US20150065381A1
(en)
|
2013-09-05 |
2015-03-05 |
International Aids Vaccine Initiative |
Methods of identifying novel hiv-1 immunogens
|
JP6499184B2
(en)
|
2013-10-07 |
2019-04-10 |
ノヴォ ノルディスク アー/エス |
Novel derivatives of insulin analogues
|
EP2873423B1
(en)
|
2013-10-07 |
2017-05-31 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
MY176976A
(en)
|
2013-10-10 |
2020-08-28 |
Bausch Health Ireland Ltd |
Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
|
PE20161413A1
(en)
|
2013-11-04 |
2017-01-10 |
Stemcentrx Inc |
ANTI-EFNA4-DRUG ANTIBODY CONJUGATES
|
CN113274506A
(en)
*
|
2013-12-05 |
2021-08-20 |
念·吴 |
Drug delivery technology of polymer-carbohydrate conjugates
|
US10092891B2
(en)
*
|
2014-04-25 |
2018-10-09 |
University Of Florida Research Foundation, Incorporated |
Controlling the activity of growth factors, particularly TGF-β, in vivo
|
KR102238032B1
(en)
|
2014-04-30 |
2021-04-08 |
화이자 인코포레이티드 |
Anti-ptk7 antibody-drug conjugates
|
CN117180445A
(en)
|
2014-05-28 |
2023-12-08 |
梅德瑞斯糖尿病有限责任公司 |
Improved peptide drugs against insulin resistance
|
KR101770664B1
(en)
*
|
2014-06-13 |
2017-08-23 |
주식회사 휴메딕스 |
Melittin-Polyethylene Glycol Conjugates and Pharmaceutical Composition Comprising the Same
|
EP3069730A3
(en)
|
2015-03-20 |
2017-03-15 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
EP3072901A1
(en)
|
2015-03-23 |
2016-09-28 |
International Aids Vaccine Initiative |
Soluble hiv-1 envelope glycoprotein trimers
|
TWI812873B
(en)
|
2015-11-30 |
2023-08-21 |
美商輝瑞股份有限公司 |
Antibodies and antibody fragments for site-specific conjugation
|
TWI726942B
(en)
|
2015-11-30 |
2021-05-11 |
美商輝瑞股份有限公司 |
Site specific her2 antibody drug conjugates
|
WO2017123634A1
(en)
|
2016-01-11 |
2017-07-20 |
Synergy Pharmaceuticals, Inc. |
Formulations and methods for treating ulcerative colitis
|
DK3506935T3
(en)
|
2016-09-02 |
2024-04-02 |
Sanofi Pasteur Inc |
Neisseria meningitidis-vaccine
|
BR112019011761A2
(en)
|
2016-12-16 |
2019-11-05 |
Novo Nordisk As |
insulin-containing pharmaceutical compositions
|
US10174302B1
(en)
|
2017-06-21 |
2019-01-08 |
Xl-Protein Gmbh |
Modified L-asparaginase
|
US11364303B2
(en)
|
2017-09-29 |
2022-06-21 |
Pfizer Inc. |
Cysteine engineered antibody drug conjugates
|
IL311775A
(en)
|
2018-01-03 |
2024-05-01 |
Mederis Diabetes Llc |
Improved peptide pharmaceuticals for treatment of nash and other disorders
|